logo

For the Inventor, By the Inventor

Rockville, MD, United States of America

Human Genome Sciences, Inc.


USPTO Granted Patents = 676

% Expired Patents = 33.6



Trademarks = 4

Forward Citations = 7,885

Loading Chart...
Loading Chart...

226 inventors (with patents filed for the assignee):

goldMedal Craig A Rosen (312 out of 329 patents)

silverMedal Steven M Ruben (254 out of 266 patents)

bronzeMedal Jian Ni (180 out of 190 patents)

4.  Guo-Liang Yu (101 out of 142 patents)

5.  Reiner L Gentz (80 out of 82 patents)

6.  Mark D Adams (72 out of 84 patents)

7.  Henrik S Olsen (59 out of 61 patents)

8.  Haodong Li (56 out of 60 patents)

9.  Reinhard Ebner (54 out of 55 patents)

10.  Ying-Fei Wei (53 out of 56 patents)

11.  Reiner L Gentz (53 out of 59 patents)

12.  Yi Li (52 out of 62 patents)

13.  Patrick J Dillon (52 out of 62 patents)

14.  Daniel R Soppet (39 out of 40 patents)

15.  Paul A Moore (38 out of 81 patents)


Core Competencies:
Albumin Fusion Proteins
Vascular Endothelial Growth Factor
B Lymphocyte Stimulator
Antibodies
Tumor Necrosis Factor
Sialylation Pathways
Neutrokine-alpha
Cytokine Receptors
Immunoglobulin Production
Polypeptides
Human MutY
Medical Injector

676 patents:

1. 9403905 - Vascular endothelial growth factor 2 (2016-08-02),
2. 9296809 - Albumin fusion proteins (2016-03-29),
3. 9221896 - Albumin fusion proteins (2015-12-29),
4. 9187548 - Antibodies that immunospecifically bind to B lymphocyte stimulator protein (2015-11-17),
5. 9168286 - Methods and compositions for use in treatment of patients with autoantibody positive disease (2015-10-27),
6. 8993517 - Albumin fusion proteins (2015-03-31),
7. 8969538 - Albumin fusion proteins (2015-03-03),
8. 8946156 - Albumin Fusion Proteins (2015-02-03),
9. 8937169 - Human G-protein chemokine receptor HSATU68 (2015-01-20),
10. 8784809 - Vascular endothelial growth factor 2 (2014-07-22),
11. 8546105 - Engineering intracellular sialylation pathways (2013-10-01),
12. 8518389 - Methods of inhibiting proliferation or immunoglobulin production of B cells using human tumor necrosis factor receptor TR-17 polypeptides (2013-08-27),
13. 8513189 - Albumin fusion proteins (2013-08-20),
14. 8410248 - HWBAO62 polypeptides (2013-04-02),
15. 8372948 - 12 human secreted proteins (2013-02-12),
Company Overview
Human Genome Sciences, Inc., based in Rockville, MD, specializes in the development of innovative therapeutic solutions utilizing albumin fusion proteins. The company focuses on advanced research in key areas such as vascular endothelial growth factor, B lymphocyte stimulator, and tumor necrosis factor, among others. By leveraging its expertise in cytokine receptors and sialylation pathways, Human Genome Sciences aims to address significant medical needs through targeted therapies and biologics, contributing to advancements in the field of biotechnology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Human Genome Sciences, Inc. USPTO Patent Assignee Logo
676 Patents

#1 in Rockville, MD

#9 in Maryland

#739 in US

#1,470 in the World

Rockville, MD (US)
Rockville, MD, United States of America

Human Genome Sciences, Inc.

Forward Citations = 7,885

226 inventors:

goldMedal Craig A Rosen (312 out of 329 patents)

silverMedal Steven M Ruben (254 out of 266 patents)

bronzeMedal Jian Ni (180 out of 190 patents)

4.  Guo-Liang Yu (101 out of 142 patents)

5.  Reiner L Gentz (80 out of 82 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Human Genome Sciences, Inc.. Retrieved from https://idiyas.com/company/human-genome-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…